The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons
Open accessAbstract
The potential threat of biological warfare with a specific agent is proportional to the susceptibility of the population to that agent. Preventing disease after exposure to a biological agent is partially a function of the immunity of the exposed individual. The only available countermeasure that can provide immediate immunity against a biological agent is passive antibody. Unlike vaccines, which require time to induce protective immunity and depend on the host's ability to mount an immune response, passive antibody can theoretically confer protection regardless of the immune status of the host. Passive antibody therapy has substantial advantages over antimicrobial agents and other measures for postexposure prophylaxis, including low toxicity and high specific activity. Specific antibodies are active against the major agents of bioterrorism, including anthrax, smallpox, botulinum toxin, tularemia, and plague. This article proposes a biological defense initiative based on developing, producing, and stockpiling specific antibody reagents that can be used to protect the population against biological warfare threats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival
Teitelbaum, R., Glatman-Freedman, A., Chen, B., Robbins, J. B., Unanue, E., Casadevall, A., & Bloom, B. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15688 · Cited by 275
Self-citationSerum therapy revisited: animal models of infection and development of passive antibody therapy
Casadevall, A., & Scharff, M. D. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.8.1695 · Cited by 251
Self-citation
Cited by
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Self-citationProsniak, M., Faber, M., Hanlon, C. A., Rupprecht, C. E., Hooper, D. C., & Dietzschold, B. (2003) · The Journal of Infectious Diseases · doi:10.1086/375247 · Cited by 97
Immunological Responses to Envenomation
Ryan, R. Y. M., Seymour, J., Loukas, A., Lopez, J. A., Ikonomopoulou, M. P., & Miles, J. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661082 · Cited by 49
Mukherjee, J., Dmitriev, I., Debatis, M., Tremblay, J. M., Beamer, G., Kashentseva, E. A., Curiel, D. T., & Shoemaker, C. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106422 · Cited by 37
Metadata
- Authors
- Casadevall, A.
- Venue
- Emerging Infectious Diseases
- Published
- 2002-08
- Volume
- 8
- Issue
- 8
- Pages
- 833-841
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W2132239186
- Cited by
- 165
- References
- 2
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.